MY206003A - Pharmaceutical composition comprising brexpiprazole - Google Patents

Pharmaceutical composition comprising brexpiprazole

Info

Publication number
MY206003A
MY206003A MYPI2020004649A MYPI2020004649A MY206003A MY 206003 A MY206003 A MY 206003A MY PI2020004649 A MYPI2020004649 A MY PI2020004649A MY PI2020004649 A MYPI2020004649 A MY PI2020004649A MY 206003 A MY206003 A MY 206003A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical composition
brexpiprazole
granulate
relates
present
Prior art date
Application number
MYPI2020004649A
Other languages
English (en)
Inventor
Kamil Garbera
Katarzyna Wos-Latosi
Original Assignee
Adamed Pharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61768247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY206003(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adamed Pharma S A filed Critical Adamed Pharma S A
Publication of MY206003A publication Critical patent/MY206003A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2020004649A 2018-03-26 2019-03-21 Pharmaceutical composition comprising brexpiprazole MY206003A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18461541.7A EP3545950A1 (de) 2018-03-26 2018-03-26 Pharmazeutische zusammensetzung, umfassend brexpiprazole
PCT/EP2019/057016 WO2019185432A1 (en) 2018-03-26 2019-03-21 Pharmaceutical composition comprising brexpiprazole

Publications (1)

Publication Number Publication Date
MY206003A true MY206003A (en) 2024-11-23

Family

ID=61768247

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020004649A MY206003A (en) 2018-03-26 2019-03-21 Pharmaceutical composition comprising brexpiprazole

Country Status (14)

Country Link
EP (2) EP3545950A1 (de)
KR (1) KR20200136399A (de)
AU (1) AU2019245827B2 (de)
BR (1) BR112020019410A2 (de)
CA (1) CA3092948C (de)
CO (1) CO2020012962A2 (de)
EA (1) EA202092062A1 (de)
MX (1) MX2020010113A (de)
MY (1) MY206003A (de)
PH (1) PH12020551434A1 (de)
SG (1) SG11202008768VA (de)
UA (1) UA126702C2 (de)
WO (1) WO2019185432A1 (de)
ZA (1) ZA202006541B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117529309A (zh) * 2022-06-16 2024-02-06 江苏慧聚药业股份有限公司 药物组合物及依匹哌唑口溶膜
WO2025117624A1 (en) * 2023-11-28 2025-06-05 Oakwood Laboratories, Llc Microsphere formulations comprising brexpiprazole and methods for making and using the same
EP4574134A1 (de) 2023-12-22 2025-06-25 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablette mit brexpiprazol
EP4574135A1 (de) 2023-12-22 2025-06-25 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tabletten mit brexpiprazol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US9241876B2 (en) * 2011-06-27 2016-01-26 Shanghai Zhongxi Pharmaceutical Corporation Aripiprazole medicament formulation and preparation method therefor
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
CN105412036A (zh) * 2015-12-24 2016-03-23 北京康立生医药技术开发有限公司 依匹哌唑口腔崩解片

Also Published As

Publication number Publication date
CA3092948C (en) 2024-10-29
EA202092062A1 (ru) 2020-11-03
WO2019185432A1 (en) 2019-10-03
MX2020010113A (es) 2020-11-06
SG11202008768VA (en) 2020-10-29
PH12020551434A1 (en) 2021-09-01
UA126702C2 (uk) 2023-01-11
EP3773508A1 (de) 2021-02-17
ZA202006541B (en) 2021-09-29
CA3092948A1 (en) 2019-10-03
AU2019245827B2 (en) 2024-05-02
BR112020019410A2 (pt) 2021-01-05
EP3545950A1 (de) 2019-10-02
AU2019245827A1 (en) 2020-09-24
CO2020012962A2 (es) 2020-10-30
KR20200136399A (ko) 2020-12-07

Similar Documents

Publication Publication Date Title
PH12020551434A1 (en) Pharmaceutical composition comprising brexpiprazole
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12017502315A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
JO3675B1 (ar) مشتقات هيدروكسي إستر جديدة،عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
EP4269440A3 (de) Zusammensetzung zur behandlung von il-6-assoziierten erkrankungen
ECSP22032851A (es) Inhibidores del fxia y m?todo de preparaci?n de los mismos y uso farmac?utico de los mismos
SA517390586B1 (ar) مشتقات حمض هيدروكسي جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
EP3357491A4 (de) Pharmazeutische zusammensetzung mit anionischem wirkstoff und herstellungsverfahren dafür
MD4575B1 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
BR112015018087A8 (pt) composto, composição farmacêutica e uso
EA201890123A1 (ru) Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их
HK1251481A1 (zh) 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
EA201691322A1 (ru) Фармацевтическая композиция ингибитора dpp-iv в комбинации с метформином
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
EP4327804A3 (de) Verfahren zur herstellung stabiler therapeutischer glucagonformulierungen in aprotischen polaren lösungsmitteln
MX377955B (es) Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos
EA032927B1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
EA201691741A1 (ru) Фармацевтическая композиция
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
PH12017501828A1 (en) Stabilized pharmaceutical composition and method for preparing same
EA201890419A1 (ru) ОТСЕЛЕКТИРОВАННЫЙ АМИД γ-ГИДРОКСИМАСЛЯНОЙ КИСЛОТЫ И ЕГО ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗЛОУПОТРЕБЛЕНИЯ АЛКОГОЛЕМ
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
EP4537846A3 (de) Anaverx2-73 zur behandlung von morbus alzheimer
MX2020007434A (es) Formulación farmacéutica estabilizada que comprende everolimus.